CommercialCoverageMedium impact
08.02.40, Cosibelimab-ipdl (Unloxcyt™)
Independence Blue Cross·Pharmacy, Oncology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
This is a new pharmacy policy (08.02.40) for Cosibelimab-ipdl (Unloxcyt™) effective July 28, 2025. The policy establishes coverage and billing guidelines for this new medication. Billing teams must identify the specific HCPCS code and any prior authorization requirements by reviewing the full policy text at the provided URL, as the summary provided does not include specific billing codes or coverage criteria.
Action Required
By July 28, 2025: Billing team must obtain and review the complete policy text for 08.02.40 (Cosibelimab-ipdl/Unloxcyt™) at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=07&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-02-40. Identify the HCPCS J-code or other billing code for this drug and determine if prior authorization is required before submitting claims. Update billing system and encounter documentation templates with the correct code and any authorization workflow requirements. Verify coverage criteria and patient eligibility rules. Communicate requirements to providers and clinical staff. Claims submitted without proper coding or required authorization may be denied.